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Abstract
NK/T-cell lymphoma (NKTCL) is the most frequent EBV-related NK/T-cell disease. Its clinical manifestations overlap with
those of familial haemophagocytic lymphohistiocytosis (FHLH). Since PERFORIN (PRF1) mutations are present in FHLH, we
analysed its role in a series of 12 nasal and 12 extranasal-NKTCLs. 12.5% of the tumours and 25% of the nasal-origin cases
had the well-known g.272C.T(p.Ala91Val) pathogenic SNP, which confers a poor prognosis. Two of these cases had a
double-CD4/CD8-positive immunophenotype, although no correlation was found with perforin protein expression. p53 was
overexpressed in 20% of the tumoral samples, 80% of which were of extranasal origin, while none showed PRF1 SNVs. These
results suggest that nasal and extranasal NKTCLs have different biological backgrounds, although this requires validation.
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Introduction
Extranodal NK/T-cell lymphomas (NKTCLs) are the main
group of EBV-positive neoplasms that affect TNK cells, according
to the recently revised WHO classification, which also includes
aggressive NK cell leukaemia, chronic active EBV disease
(CAEBV), severe mosquito bite allergy and hydroa vacciniforme.
The precise role of EBV in the aetiology of the disease is poorly
understood, although the incidence of NKTCL and the other
EBV-associated lymphoproliferative disorders (LPDs) parallels the
geographic distribution of EBV infection (in Asian and Central
and South American populations) [1]. Most NKTCLs probably
originate from mature NK cells, while a small proportion of cases,
which express ab or cd TCR, appear to derive from cytotoxic T-
lymphocytes (CTLs). They usually arise as tumours or destructive
lesions in the nasal cavity, maxillary sinuses or palate. More rarely,
they can appear in other extranodal sites, such as the skin, testis,
lung or gastrointestinal tract. Despite their localised presentation
in most patients, NKTCL is an aggressive lymphoma associated
with a median survival for advanced-stage disease of only 6–12
months. NKTCL has a wide cytological spectrum and is
characterised by angioinvasion and angiodestruction, leading to
coagulative necrosis. Tumoral cells usually express cytoplasmic
CD3, CD2 and, less frequently, CD56, and strongly express
cytotoxic markers, including TIA-1, granzyme B and perforin
[2,3,4].
Perforin is a 67-kDa pore-forming protein that, in mammals, is
uniquely expressed in CTL [5,6]. The complete absence of PRF1
function typically results in an aggressive, fatal immunoregulatory
disorder of early childhood known as type 2 familial haemopha-
gocytic lymphohistiocytosis (FHLH). The overall frequency of
PRF1 mutations in FHLH is between 15% and 50% and depends
on the geographical and ethnic origin of the patients [7]. FHLH
and EBV-associated haemophagocytic lymphohistiocytosis (EBV-
HLH) have overlapping clinical manifestations, whereby CAEBV
is often associated with EBV-HLH and some EBV-associated LPD
patients eventually evolve into proper NKTCL cases [8,9].
Interestingly, a case of CAEBV with a mutated PRF1 gene has
been described [10], and a girl initially diagnosed with EBV-HLH
carrying a PRF1 gene mutation (S168N) finally developed an
NKTCL [11].
The aim of the study reported in this paper was to establish
whether PRF1 mutations are present in NKTCLs. We analysed a
series of 24 consecutive NKTCLs, 12 each of nasal and extranasal
origin, and found two PRF1 single-nucleotide variations (SNVs) in
16.6% of the cases. These SNVs were the well-known pathogenic
SNP g.272C.T(p.Ala91Val) and the hitherto unreported
c.289G.A(p.Ala97Thr). The p.Ala91Val SNV was present in
12.5% of all cases analysed, which is twice the percentage of cases
expected for a Caucasian population (3% in heterozygosity
according to http://www.ncbi.nlm.nih.gov/SNP/snp;rs = rs35947
132). These data are remarkable, since NKTCLs account for no
more than 1% of all lymphomas in Europe. Furthermore, all
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91521
positive cases were of nasal origin (33.3%), had a peculiar CD4/
CD8-positive phenotype, exhibited no correlation with perforin
expression, and conferred a poor prognosis on patients (median
overall survival of 9.5 months compared with 25.54 and 10.6
months for nasal and extranasal-NKTCLs, respectively). Interest-
ingly, in the present series, p53 was overexpressed in 20% of the
tumoral samples, of which 80% were of extranasal origin, and
none exhibited PRF1 SNVs. These data suggest a specific
background susceptibility to the development of this subgroup of
tumours, at least in the Spanish population. However, a larger
series of patients are needed to validate this finding.
Materials and Methods
Tissue samples
We analysed a series of 24 consecutive NKTCL cases submitted
for diagnosis or a second opinion to the CNIO Pathology
Laboratory between 2000 and 2010. Criteria for the diagnosis of
NKTCLs were based on the WHO classification [12]. Complete
clinical data were obtained from 21 patients. All patients who were
alive at the end of the study or the direct relatives of deceased
patients provided their written consent to participate. This specific
project was supervised and approved by the Ethical Committee of
the Hospital Carlos III, Madrid, and Hospital Universitario
Marqués de Valdecilla, Santander.
Tissue microarray construction
Representative areas from formalin-fixed, paraffin-embedded
lymphomas were carefully selected on H&E-stained sections and
two 1-mm-diameter tissue cores were obtained from each
specimen. The tissue cores were precisely arrayed into a new
paraffin block using a tissue microarray (TMA) workstation
(Beecher Instruments, Silver Spring, MD), following previously
described methods [13].
Immunohistochemistry
TMA sections were immunohistochemically stained using the
Endvision method with a heat-induced antigen-retrieval step.
Sections were immersed in boiling 10 mM sodium citrate at
pH 6.5 for 2 min in a pressure cooker. A panel of eight antibodies
(CD3, CD4, CD8, CD56, p53, CD117, beta-catenin and perforin)
were analysed (Table 1). Cases were considered positive whether
the protein was present in more than 10% of the neoplastic cells.
Perforin was analysed with respect to the presence or absence of
the protein, the intensity of staining and the pattern of distribution
of the granules. Three categories were created based on the
intensity of staining: low, intermediate and high. Two groups were
recognised, based on the distribution of the granules: a granular
pattern limited to the Golgi region or one diffusely distributed
throughout the cytoplasm. EBER-positive cells were considered to
be neoplastic. Consecutive EBER-positive sections of each case
were evaluated to quantify perforin staining. Reactive tonsil tissue
was included as a control. The primary antibodies were omitted to
provide negative controls.
EBV in situ hybridisation (EBER)
The presence of EBV RNA was established by non-isotopic in
situ hybridisation with EBV-encoded RNA (EBER) 1 and 2
oligonucleotide probes (Dakocytomation) in paraffin-embedded
tissue sections, as previously described [14].
PRF1 gene sequencing
Exons 2 and 3 of the PRF1 gene have been amplified and
sequenced with the primer sets shown in Table 2. Tissue sections
from all cases contained between 50% and 80% tumoral cells. The
50-ml PCR reaction volume contained 0.2 mM of each dNTP, 1
unit Taq full DNA polymerase (Clontech Laboratories, Inc.),
0.2 mM of each of the forward and reverse primers and 100 ng of
genomic DNA. After initial denaturation at 94uC for 2 min, 35
cycles of 15 s at 94uC, 30 s at 60uC and 30 s at 72uC were run in
an MBS Satellite Thermal Cycler (Thermo Scientific). The
expected size of the amplified PCR products (Table 2) was
determined on an agarose gel with a 100-bp high-range ladder
DNA size standard, and the amplified fragments were purified
using the MSB Spin PCRapace (Invitek) system and sequenced by
means of the dideoxy procedure with the BigDye Terminator v3.1
Cycle Sequencing kit (Life Technologies) and the same primers as
for PCR, and analysed with a 3130XL ABI Genetic Analyzer and
SeqScape v2.5 software (Life Technologies). PCR products from
all cases were sequenced in duplicate from both strands and only




There were 11 males and 13 females, with a median age at
diagnosis of 56.6 years (range, 31–89 years). In 12 cases the lesion
was initially nasal, two cases each had oropharingeal tumours or
involvement of the gastrointestinal tract, six cases involved skin
and subcutis, and one case each affected pleura and testis,
respectively. We obtained complete clinical data from 21 cases,
whose median follow-up was of 18.4 months (range, 1–121
months). None of the patients was referred with haemophagocytic
syndrome or leukaemic involvement of the peripheral blood. One
patient had previously had a renal transplant, one was HIV-
positive and another was HCV-positive. At initial diagnosis the
Ann Arbor Stage was low (I–II) in seven and two, and high (III–
IV) in five and six nasal and extranasal lymphoma patients,
respectively. The frequencies of IPI classes for nasal and extranasal
cases at diagnosis were: low (four and two patients, respectively),
low-intermediate (four and one), intermediate-high (zero and
three) and high (two and two). The frequency across PIT classes at
presentation was low (eight nasal and three extranasal cases), low-
intermediate (one and four), intermediate-high (one and one) and
high (zero and zero). First-line therapy was with CHOP or
CHOP-like regimens (CHOP-14, CHOP-21, Mega-CHOP) in 18
patients, followed by local radiotherapy in four patients. Three
patients received radiotherapy alone and another one underwent
local excision and was administered steroids. Two patients
received further autologous stem cell transplantation, and in five
cases other second line chemotherapeutic regimens, such as
SMILE, alemtuzumab, HPER-CVAD, ESHAP and IEV, were
also applied. Seventeen patients died of the disease (nine of nasal
and eight of extranasal origin) while four remained alive at last
follow-up. The median overall survival for patients with nasal and
extranasal NKTCLs was 25.54 (range, 2–121) and 10.6 (range, 1–
80) months, respectively (Table 3).
Immunohistochemical and in situ hybridisation
characteristics
EBER and CD3 were positive in all cases, 75% expressed CD56
and there were six CD8-positive, two double-CD8/CD4-positive
and 14 double-CD8/CD4-negative cases. Perforin was expressed
in 23 (95.8%) of the 24 cases, the intensity of staining being strong
in 26.1%, moderate in 43.5% and low in 30.4% of them. Neither
CD117 nor beta-catenin was positive in any of the cases, while p53
PRF1 Gene in NK/T-Cell Lymphomas
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was intensively positive in five of 22 (22.7%) cases (Table 3 and
Figure 1).
Mutational studies
Three cases were heterozygous for the g.272C.T, p.Ala91Val
SNV (12.5%). This is a well-known SNP and the most common
base substitution identified in the PRF1 gene [5]. Interestingly, the
substitution of c.289G.A resulting in the amino acid residue
change p.Ala97Thr in the PRF1 gene was found in one other case
(2.16%). This SNV was not found in any of the SNP databases
(dbSNP137; Hapmap; 1000 genomes) or in the COSMIC
database (Table 3). Unfortunately, we did not have normal
DNA of the patient to rule out the possibility of it being present in
the germline. Additionally, 25% of patients showed other SNPs;
four patients had the c822C.T; pAla274Ala SNV (all heterozy-
gous), while six showed the g.900C.T; p.His300His SNV (five
heterozygous and one homozygous).
All cases with potential pathological PRF1 SNVs were of nasal
origin, representing 25% (3 of 12) of all nasal cases, or 33.3%
when considering all the PRF1 SNVs. Moreover, three of the four
cases with PRF1 SNV died of the disease, following an overall
survival of 9.5 months (range, 2–21 months). These data are more
in accordance with the outcome of extranasal than with nasal
patients. Two of these cases were those that were double-positive
for CD4 and CD8, and one appeared in the tumoral tissue of the
renal posttransplant patient. Neither intensity of staining nor the
pattern of granule distribution was related to the presence of PRF1
SNVs.
On the other hand, none of the p53-positive cases showed PRF1
SNVs, and 80% were of extranasal origin. All cases were double-
CD4/CD8-negative, and mainly had a cytoplasmic pattern of
perforin expression. All these patients died after a median period
of 4.2 months (Table 3).
Discussion
We report for the first time the presence of the g.272C.T,
p.Ala91Val SNV of the PRF1 gene in NKTCLs. We found it in
12.5% of our cases, which is more than twice the percentage of
cases expected in a Caucasian population (3% in heterozygosity
according to http://www.ncbi.nlm.nih.gov/SNP/snp;rs = rs35947
132). These frequencies are remarkable, since NKTCLs account
for no more than 1% of all lymphomas in Europe.
The pathogenic role of the g.272C.T variant has long been
controversial [15,16], although it is accepted that this SNV leads
to reduced cytotoxic activity of the perforin protein due to
incorrect folding that decreases its cleavage to the active form and
increases its degradation [5,7,17,18,19]. Such a reduction in the
level of activity could predispose an individual to late or atypical
FHLH, and the development of anaplastic large cell lymphomas,
B- and T-cell lymphomas and acute childhood lymphoblastic
leukaemia carrying the BCR-ABL fusion gene [7,20,21,22,23].
Except for the ALCL cases described by Cannella et al [21] none
of the other T-cell lymphoma cases exhibiting A91V SNV have
been correctly categorised according to the current WHO
classification. Cannella et al [21] described this SNV in
heterozygosity in eight of the 12 patients in which they found
other PRF1 gene mutations. Clementi et al reported a series of
eight cases with equal numbers showing PRF1 gene mutations in
homozygosis and heterozygosity. A91V SNV was heterozygous in
three of them, one of the cases being a T-cell non-Hodgkin
lymphoma (NHL) [24]. Moreover, a PRF1 gene mutation was
described in two cases of subcutaneous panniculitis-like T-cell
lymphoma [24,25]. One patient presented the 1168C.T
(Arg390stop) in a single allele and the other had two mutations,
the 272C.T (A91V) and the 1262G.T (Phe 421Cys), in
heterozygosity. Both patients suffered from HLH, a widely
described phenomenon in both subcutaneous panniculitis ab
and cd T-cell lymphomas [26].
Except for the double-CD4/CD8 positivity of two cases, which
is rare [25,27], all other immunophenotypes of the cases presented
Table 1. Antibodies used in this series.
Antibody Clone Source Dilution Method (Automated) Antigen Retrieval
CD3 FLEX Polyclonal Rabbit Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
CD4 FLEX 4b12 Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
CD8 FLEX C8/144b Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
CD56 FLEX 1b6 Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
PERFORINA 5d10 Novocastra 1:25 AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
P53 Do7 (mouse) Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
BETA-CATENIN Beta-catenin-1 (mouse) Dako Ready to use AUTOSTAINER (Dako Cytomation) TRIS EDTA, 20 MIN
CD117 (C-KIT) Rabbit polyclonal Dako 1/200 AUTOSTAINER (Dako Cytomation) CITRATE, 20 MIN
doi:10.1371/journal.pone.0091521.t001
Table 2. Primers used to amplify most of the exon 2 and 3
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here were in accordance with previous reports [4,28,29].
Interestingly, these two double-CD4/CD8-positive cases carried
the A91V SNV. In the present study, perforin was present in all
but one (95.8%) case, although the pattern and intensity of
expression varied from case to case. In the various series reported,
perforin-positive cases account for 65–86% of NKTCLs
[27,30,31,32], perforin losses being related to poor outcome
[27]. In the present study, neither intensity of staining nor the
pattern of granule distribution was associated with the presence of
the A91V SNV.
The expression of other genes frequently found mutated in
cancer and NKTCLs were also investigated in these series. Intense
p53 staining was found in 22.7% of cases, while none of them
expressed either CD117 or beta-catenin. Interestingly, none of the
p53-positive cases showed PRF1 SNVs, all were double-CD4/
CD8-negative, and mainly had a cytoplasmic pattern of perforin
expression.
The frequencies of mutations of p53, KIT and CTNNB1 genes in
NKTCLs varied between Asian countries and the rest of the
world, suggesting that the development of these mutations is
influenced by geographical, environmental and ethnic differences,
as has been discussed by many authors [33,34,35,36,37,38].
Moreover, there is a well-known discrepancy in the positive rates
between mutational and expression studies [33,34,35,36,37,
38,39]. The highest percentages of cases with mutated KIT and
CTNNB1 genes have been found in China (11.1%) and Japan
(30.0%). Recently, Huang et al were unable to demonstrate
nuclear beta-catenin expression, a result that accords with our
findings [40]. The highest known rates for p53 mutation are those
for Japan and Indonesia, where it was found in 62% and 63% of
cases, respectively. The lowest mutation rates have been found in
Korea (31% of cases) and Mexico (24%) [3]. Moreover,
Quintanilla et al showed that the p53 mutation is related to large
cell morphology and advanced disease stage [35]. Quintanilla et al
reported 60% and 86% of p53-positive cases in Mexican and
Peruvian populations, respectively [35,41]. Pongpruttipan et al
[29] found 68% of their cases from the Thai population to be
positive, while Ye et al [42] found 33.3% of cases to be positive in
the Chinese population. The latter two groups exhibited close
correlation between p53 expression and both prognosis and
advanced disease stage. This and all previously reported studies
were done with the same Dako antibody for p53 and using the
same cut-off value (.10% positive tumoral cells) to define
positivity, with the exception of Ye et al, who used a value of
5%. However, the Quintanilla et al study included exclusively
nasal NKTCLs while the others combined nasal and extranasal
NKTCL cases in their analyses. In the present series, only one of
the five positive cases was of nasal origin, representing 8.3% (one
out of 12) of them, while 33.3% of those NKTCLs of extranasal
origin (four out of 12) had p53 expression. These data suggest that
Table 3. Most relevant immunohistochemical and clinical data of these series.
CASE MUTATION SEX AD LDD P53 CD56 CD8 CD4 PI PG STATUS OS (months)
1 NMF M 77 Nasal tissue N HI N N N NP A 121
2 NMF M 50 Skin N HI HI N Mo GR NK NK
3 NMF M 57 Nasal tissue N LI N N L GR D 10
4 g.272C.T; Ala91Val M 71 Nasal tissue N N HI P Mo GR D 2
5 NMF M 47 Skin N N LI N L GR A 80
6 NMF F 75 Nasal tissue N N N N Mo GR D 45
7 NMF M 46 Testis N LI N N Mo TC D 1
8 NMF M 53 Nasal tissue NV HI NV N Mo TC NK NK
9 NMF F 69 Pleura P HI N N Mo TC D 2
10 NMF F 31 Pharynx N HI N N H GR NK NK
11 NMF F 53 Nasal tissue N N N N L GR D 10
12 NMF F 43 Nasal tissue P HI N N H TC D 6
13 NMF F 68 Skin P HI N N Mo TC D 6
14 NMF M 78 Nasal tissue N HI N N H GR A 32
15 NMF F 34 Intestine NV N N NV H GR D 3
16 NMF F 31 Stomach P HI N N Mo TC D 4
17 NMF F 89 Soft tissues P HI N N Mo GR D 3
18 NMF F 62 Oral cavity N N HI N L GR D 1
19 NMF M 78 Skin N LI HI N L GR D 5
20 g.272C.T; Ala91Val F 48 Nasal tissue N HI HI N M TC A 21
21 c.289G.A;
pAla97Thr
M 64 Nasal tissue N HI N N M GR D 13
22 NMF F 27 Skin N HI N N M TC D 1
23 g.272C.T; Ala91Val F 52 Nasal tissue N HI LI P H GR D 2
24 NMF M 57 Nasal tissue N HI HI N H GR D 19
NMF:No mutation found; M:Male; F:F; AD:Age at Diagnosis; LDD:Location of the disease at Diagnosis; N:Negative; P:Positive; NV: Not evaluable; HI: High-Intensity; LI:Low-
Intensity; L:Low; Mo:Moderate; NP: Not present; NK: Not Known; PI:Perforin Intensity; PG: Perforin Granules; GR: Golgi Region; TC: Troughout the cytoplasm; A: Alive;
D:Dead; OS: Overall Survival.
doi:10.1371/journal.pone.0091521.t003
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p53 expression in NKTCLs in the Spanish population is also
different from that in other regions of the world. Nevertheless, in
considering all the data from the present study, all of the positive
cases were III/IV stage patients, while 52.9% and 29.4% of the
negative cases were high- and low-stage patients, respectively.
We found the PRF1 gene A91V SNV in 25% of nasal NKTCLs
but in none of the extranasal ones, while 80% of p53-positive cases
were extranasal in origin. Several papers have concluded that the
clinical features and treatment response of extranasal and nasal
NKTCLs are different [43,44,45,46,47,48], consistent with the
results we present herein. Nevertheless, the underlying features
responsible for these differences remain to be determined. On the
other hand, some authors have suggested that nasal and extranasal
NKTCLs behave alike at the same stage of the disease [46,47].
One publication addressing this subject has suggested that there
are different genetic alterations in the two subgroups [49]. Nasal
NKTCL patients with PRF1 SNVs seem to behave more
aggressively than those without it. The median overall survival
of nasal NKTCL patients in our series was 25.5 months, while that
of patients carrying PRF1 SNVs was 9.5 months. On the other
hand, p53-positive patients died after a median period of 3.7
months (4.2 months when nasal cases were included), while the
value for the entire subgroup of extranasal NKTCLs was 10.6
months. Interestingly, only one of the three nasal NKTCLs
carrying the PRF1 SNVs for whom complete clinical data were
available had stage IV disease, while the others were stage I and II.
Figure 1. An A91V SNV-positive case (A-HE, staining, B-EBER-positive) showing negativity for p53 (C) and low-level of perforin
expression (D). An A91V SNV-negative case (E-HE, staining, F-EBER-positive) showing intense expression of p53 (G) and perforin (H).
doi:10.1371/journal.pone.0091521.g001
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In addition, the nasal case and three of the four cases positive for
p53 for whom clinical data were complete were stage III and IV,
respectively.
The pathogenic role of this PRF1 SNV has been demonstrated
and p53 expression is in most cases a surrogate marker for the P53
gene mutation. The fact that none of the cases carrying PRF1
SNVs showed p53 expression suggests the role of different
pathways in the two diseases. Considering these findings together,
leads us to conclude that nasal and extranasal NKTCLs may have
different biological backgrounds. Our series was too short to
warrant statistical analysis, so a larger series of patients is needed to
confirm our findings.
In conclusion, we suggest that the g.272C.T PRF1 gene SNV
in combination with other gene alterations could increase the risk
of developing nasal NKTCL, at least in a subgroup of the Spanish
population. Moreover, the presence of p53 in 80% of extranasal
NKTCLs not carrying the PRF1 gene SNV suggests there is a
different biological background in nasal and extranasal NKTCLs.
However, a larger series of patients, stratified by origin and stage
of disease and treated in a uniform way needs to be studied to
validate our preliminary findings.
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